ADAGENE INC - ADS, EACH REPRESENTING 1.25
ADAGENE INC - ADS, EACH REPRESENTING 1.25
Certificado de depósito · US0053291078 · ADAG · A2QN45 (XNAS)
Resumen
1,99 USD
8,15 % 0,15 USD
NASDAQ (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 19:59

Cotizaciones actuales de ADAGENE INC - ADS, EACH REPRESENTING 1.25

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
ADAG
USD
06.06.2025 19:59
1,99 USD
1,76 USD
+13,07 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % 2,58 % 24,37 % -3,86 % -3,16 % -33,22 % -93,36 %

Perfil de la empresa para ADAGENE INC - ADS, EACH REPRESENTING 1.25 Certificado de depósito

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Datos de la empresa

Nombre ADAGENE INC - ADS, EACH REPRESENTING 1.25
Empresa Adagene Inc.
Símbolo ADAG
Sitio web https://www.adagene.com
Mercado principal XNAS NASDAQ
WKN A2QN45
ISIN US0053291078
Tipo de valor Certificado de depósito
Sector Healthcare
Industria Biotechnology
CEO Dr. Peter P. Luo Ph.D.
Capitalización de mercado 54 Mio
País China
Moneda USD
Empleados 0,1 T
Dirección Building C14, 215123 Suzhou
Fecha de OPV 2021-02-09

Símbolos de cotización

Nombre Símbolo
Frankfurt 978.F
NASDAQ ADAG

Otras acciones

Los inversores que tienen ADAGENE INC - ADS, EACH REPRESENTING 1.25 también tienen las siguientes acciones en su cartera:
GREAT HALL MORTGAGES NO.1 PLC CLASS A2A FR RES MTG BKD NTS18/03/39
GREAT HALL MORTGAGES NO.1 PLC CLASS A2A FR RES MTG BKD NTS18/03/39 Bono
REPSOL S.A.  ADR 1
REPSOL S.A. ADR 1 Acción
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025